• VolitionRx highlighted an asset-light strategy focused on licensing diagnostics IP, targeting multiple human-health licensing deals in 2026.
• Veterinary business showed $23 million in licensing to date, with $1 million of revenue in Q1 2026.
• Fujifilm Vet Systems launched Nu.Q Vet Cancer Test automation on the IDS i10 platform, supporting higher-throughput canine cancer screening.
• Feline lymphoma manuscript submission set up a potential $5 million contractual milestone payment if published.
• French government-backed DETECSEPS sepsis program is on track for first patient enrollment in Q3 2026; reimbursement submission is in preparation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.